Precision medicine means nobody is just ‘average’
Prostate cancer survivor Bryce Olson says genomic sequencing shows the way forward in cancer treatment, rather than the one-size-fits-all approach.
CareFirst BCBS, ExoDx band together on studies for diagnostic tests
Through CareFirst's new HealthWorx program, the organizations are working together on evidence development studies for ExoDx diagnostic tests.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
We’re not done with chemotherapy, so why not improve it?
While it's hard to get excited about a modified chemotherapy drug in an era of personalized medicine, checkpoint inhibitors, and CAR-T immunotherapies, Modra Pharmaceuticals' modified taxane drugs could make a sizeable impact in the field.
ASCO 2017 ushers in “a new chapter” for prostate cancer
In an interview at ASCO 2017, head of the Prostate Cancer Foundation Jonathan Simons was heralding one of the biggest strides the field has seen in treating the most advanced form of the disease.
Advantagene raising $35M for prostate cancer vaccine
The company is developing a prostate cancer vaccine called ProstAtak that's in Phase 3 development - though its gene-mediate cytotoxic approach could be applied to several other solid tumor cancers, the company says.
Precision Biopsy brings in $33.6M for its real-time prostate tissue biopsy platform
Precision Medicine's ClariCore Biopsy System could make biopsies of prostate tissue more accurate and efficient with results provided in real-time for patients.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
MDxHealth buys liquid biopsy prostate cancer test for $8.8M
MDxHealth, the maker of prostate cancer diagnostics, just acquired Dutch liquid biopsy company NovioGendix for $8.8 million. With the new urine-based test, slated for release next year under the name SelectMDx, it aims to reduce unnecessary biopsies for prostate cancer.
Here are some of Google’s health drawings that will now accompany its online health searches
As reported this morning, Google unveiled its new efforts to bring more accurate medical information to the online world, in a unique partnership with the Mayo Clinic. With health and medical searches accounting for one in 20 of all searches, it’s not difficult to fathom why the search engine giant and Mayo Clinic, already a […]
Viamet spinout Innocrin Pharma raises $8M for hard-to-treat prostate cancer
Innocrin Pharmaceuticals, the spanking-new spinout of successful antifungal company Viamet, just raised $8 million according to regulatory filings. The company has taken Viamet’s findings and translated them as a therapy for a tough-to-treat form of prostate cancer. This past October, Viamet withdrew its plans to go public in favor of raising $60 million in private equity […]
Who knew mustaches could raise $559 million?
The Movember mission is pretty straightforward: Men shave their facial hair at the start of November, and throughout the month, trim and tailor their own unique mustache as an effort to bring awareness to men’s health, including prostate and testicular cancer. The Movember Foundation launched 11 years ago in Australia and holds its global campaign annually […]
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Urologists v. Rad Oncs: New test shifts how doctors plan prostate cancer treatment
There are myriad prostate cancer screeners on the market, but a San Diego company’s test has an interesting spin: Researchers have found that the results of GenomeDx’s Decipher diagnostic shifts the way physicians recommend treatment for the disease, as seen in a recent Red Journal paper. The company’s genomic test, which it’s commercializing now, predicts the probability […]
ASU spinout lands $4M for early-stage cancer detection diagnostic, piques US military interest
HealthTell Inc., an Arizona State University spinout, has raised $4 million to commercialize a test for lung, breast, prostate and colorectal cancer. The Chandler, Ariz.-based startup is working to develop a variety of health monitoring tools to check the status of patients who are battling any of 30 illnesses, ranging from cancer to infectious disease. […]
New non-invasive test for prostate cancer may identify severity of tumor also
Exosome Diagnostic, Inc., has developed a revolutionary non-invasive approach to molecular diagnostic testing that is gaining popularity, especially in the field of prostate cancer detection and prognosis. The company, based in New York, was founded in 2008 and has licensed its proprietary exosome technology from Massachusetts General Hospital for use in the development of […]
The Omega-3/Prostate Cancer Media Fiesta — Mistaking Correlation for Causation Puts Patients at Risk
In recent days, medical news headlines have been dominated by a new study that linked omega-3 plasma levels to an increased risk of aggressive prostate cancer. Published in the Journal of the National Cancer Institute, results from Dr. Theodore Brasky and colleagues certainly contribute to the evidence-base for omega-3 fatty acids and prostate cancer. Yet […]
Mainstream medicine moves beyond a one-size-fits-all approach to prostate cancer screening
For nearly a quarter century, doctors have ordered annual PSA tests for men of a certain age to screen for prostate cancer, despite a lack of evidence that the benefits outweighed the risks -- especially when tiny, slow-growing tumors were detecte...